Literature DB >> 36103016

MiR-203a-3p, miR-204-3p, miR-222-3p as useful diagnostic and prognostic tool for thyroid neoplasia spectrum.

Stefana Stojanović1, Zorana Dobrijević2, Sonja Šelemetjev1, Ilona Đorić1, Jelena Janković Miljuš1, Vladan Živaljević3, Tijana Išić Denčić4.   

Abstract

PURPOSE: The challenge in the diagnosis and treatment of thyroid carcinoma is to correctly classify neoplasias with overlapping features and to identify the high-risk patients among those with a less aggressive form, in order to personalize the treatment of thyroid carcinoma patients accordingly.
METHODS: MiR-203a-3p, miR-204-3p, and miR-222-3p levels were determined in 99 cases of thyroid neoplasias (77 papillary thyroid carcinomas (PTC) of diverse variants, 12 follicular thyroid adenomas (FTA) and 10 nodular goiters (NG)) along with 99 adjacent non-malignant thyroid tissues using quantitative RT-PCR. The results were evaluated in comparison with the clinicopathological features of the patients and available TCGA data.
RESULTS: Down-regulated miR-203a-3p indicates the presence of thyroid tumor (PTC or FTA) with high sensitivity (75%) and specificity (73%), while its up-regulation indicates NG. If miR-203a-3p is down-regulated, up-regulated miR-204-3p with high sensitivity (83.3%) and specificity (74.4%) indicates FTA presence, while up-regulated miR-222-3p, with high sensitivity (76.6%) and specificity (75.0%), points to PTC. The expression of miR-204-3p and miR-222-3p depends on the PTC subtype (P < 0.05). While the deregulated expression of tested miRs is associated with a long-range of unfavorable clinicopathological parameters of PTC, only abundant expression of miR-222-3p may be used as an independent predictive factor for the presence of extrathyroid invasion and advanced pTNM stage of PTC (P < 0.05).
CONCLUSION: Successive evaluation of miR-203a-3p, miR-204-3p, and miR-222-3p expression can help in the differential diagnosis of thyroid neoplasias. A high relative value of miR-222-3p expression is an independent predictive factor for the presence of extrathyroid invasion and advanced pTNM stage of PTC. The panel consisting of miR-203a-3p, miR-204-3p, and miR-222-3p could be used as a diagnostic and prognostic tool for personalizing the treatment of thyroid cancer patients.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Aggressiveness; Differential expression; Papillary thyroid carcinoma; Tumor marker; microRNA

Year:  2022        PMID: 36103016     DOI: 10.1007/s12020-022-03185-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  30 in total

Review 1.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

Review 2.  The diverse functions of microRNAs in animal development and disease.

Authors:  Wigard P Kloosterman; Ronald H A Plasterk
Journal:  Dev Cell       Date:  2006-10       Impact factor: 12.270

Review 3.  An overview of microRNAs: Biology, functions, therapeutics, and analysis methods.

Authors:  Kioomars Saliminejad; Hamid Reza Khorram Khorshid; Shahrzad Soleymani Fard; Seyed Hamidollah Ghaffari
Journal:  J Cell Physiol       Date:  2018-11-23       Impact factor: 6.384

Review 4.  Pitfalls in the diagnosis of follicular epithelial proliferations of the thyroid.

Authors:  Ozgur Mete; Sylvia L Asa
Journal:  Adv Anat Pathol       Date:  2012-11       Impact factor: 3.875

Review 5.  Thyroid tumors with a follicular growth pattern: problems in differential diagnosis.

Authors:  Saul Suster
Journal:  Arch Pathol Lab Med       Date:  2006-07       Impact factor: 5.534

6.  Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

Authors:  F D Gilliland; W C Hunt; D M Morris; C R Key
Journal:  Cancer       Date:  1997-02-01       Impact factor: 6.860

7.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

8.  Current thyroid cancer trends in the United States.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-04       Impact factor: 6.223

9.  Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients.

Authors:  Maria Rosa Pelizzo; Isabella Merante Boschin; Antonio Toniato; Andrea Piotto; Costantino Pagetta; Milton D Gross; Adil Al-Nahhas; Domenico Rubello
Journal:  Clin Nucl Med       Date:  2007-06       Impact factor: 7.794

Review 10.  Pitfalls in Challenging Thyroid Tumors: Emphasis on Differential Diagnosis and Ancillary Biomarkers.

Authors:  José Manuel Cameselle-Teijeiro; Catarina Eloy; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2020-07-06       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.